The Roundup litigation hit two major milestones in September 2026: a $7.25 billion class action settlement reached its final court approval hearing, and a Missouri appellate court upheld a $611 million jury verdict against Monsanto for three plaintiffs. Both developments affect the tens of thousands of people still holding active non-Hodgkin lymphoma claims against Bayer and its Monsanto subsidiary.
The $7.25 Billion Settlement: Where Things Stand
Bayer proposed the $7.25 billion class action settlement in February 2026 to resolve current and projected future claims alleging that glyphosate, the active ingredient in Roundup, causes non-Hodgkin lymphoma. The court granted preliminary approval in March 2026. In mid-September, Judge Timothy Boyer of the St. Louis Circuit Court heard final approval arguments.
The settlement would cover approximately 60,000 to 65,000 active pending claims in state and federal courts, along with a claims process for future claimants who have not yet filed. Under the proposed payout structure, individual compensation would range from roughly $6,000 to $165,000, adjusted based on exposure duration, the claimant’s age at diagnosis, and the severity of illness. Payments would be funded through capped, declining annual installments from Bayer over up to 21 years.
At the September hearing, the court heard from both supporters and approximately 135 objectors — primarily plaintiff attorneys who argued the proposed payout tiers are inadequate given the volume of evidence connecting glyphosate to cancer. Bayer’s legal team told the court this represents the company’s final settlement offer. Judge Boyer took the matter under advisement and invited post-hearing submissions before issuing a ruling.
Supreme Court Ruling Reshaped the Litigation’s Future
Underneath the settlement negotiations sits a major legal shift: in June 2026, the U.S. Supreme Court ruled in Bayer’s favor on federal preemption grounds. The Court held that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) limits state-level “failure to warn” claims against Monsanto, the theory on which most Roundup verdicts have been built.
The ruling significantly constrained the legal path for future plaintiffs who have not yet settled. Failure-to-warn claims — arguing that Roundup’s label didn’t adequately disclose cancer risk — were the central theory in nearly every Roundup trial that resulted in a plaintiff verdict. With that theory substantially preempted under federal law, future cases face a steeper evidentiary climb.
The Supreme Court ruling is a primary reason Bayer has pushed aggressively for the $7.25 billion global resolution now. A settlement that looked expensive before the ruling looks considerably more palatable to plaintiffs’ counsel after it — particularly for clients whose cases have not yet gone to trial.
The $611 Million Missouri Verdict Stands
On the verdict side, September 2026 brought a significant development in the other direction. A Missouri appellate court affirmed a $611 million jury verdict against Monsanto for three plaintiffs. The verdict, which had been appealed after the original trial award, survived judicial review — giving plaintiffs who have already obtained verdicts a confirmed path to recovery.
That affirmation matters because it demonstrates that even under the shadow of the Supreme Court’s preemption ruling, some verdict theories survived and are being paid. For claimants already in trial posture, it also signals that appellate courts are not automatically reversing Roundup verdicts on preemption grounds.
What This Means for People Diagnosed with Non-Hodgkin Lymphoma
The Roundup litigation affects people who were regularly exposed to glyphosate — through farm work, groundskeeping, lawn care, or residential herbicide use — and later developed non-Hodgkin lymphoma or one of its subtypes.
If the $7.25 billion settlement receives final court approval, claims filed under that agreement will be processed through the settlement’s tier structure. People who opted out of the class settlement retain the right to pursue individual litigation, though the Supreme Court ruling substantially alters the legal landscape for those cases.
For anyone with a pending claim or a recent NHL diagnosis linked to Roundup exposure, understanding how the settlement terms apply — or whether opting out makes sense given your specific diagnosis, exposure history, and case posture — requires individualized legal evaluation. A toxic tort lawyer familiar with the Roundup MDL and the post-Supreme Court litigation environment can assess how these developments affect your specific options.
More than $11 billion in Roundup-related settlements have been paid since 2020, when Bayer first resolved over 100,000 claims for approximately $10.9 billion. The current settlement, if approved, would add substantially to that total and attempt to close out the remaining active cases and future claims in a single global resolution. A mass tort attorney can explain what participation in that settlement or opting out means as a practical matter. You can also consult a product liability lawyer to evaluate whether your individual case warrants separate litigation.
